ArticleAlzheimer's & dementia (Amsterdam, Netherlands)

Semaglutide attenuates a proteomics-based dementia risk signature in older adults with overweight or obesity and cardiovascular disease without diabetes: A post hoc analysis of the SELECT phase 3 trial.

Martí Jiménez-Mausbach et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.